Stay informed about TMS therapy, Spravato, and mental health. Expert perspectives from our clinical team.
0:36John Cavanagh introduces Restore Brain — a clinic specializing in treatment-resistant depression using cutting-edge interventional psychiatry, including TMS and other treatments that go beyond traditional medication.
1:48Bipolar disorder often starts as adolescent depression and is frequently misdiagnosed as MDD. Knowing the difference is critical because antidepressants can trigger dangerous manic episodes in bipolar patients.
0:42Low dopamine drives hyperactivity, impulsivity, and risk-taking behavior — and can increase the likelihood of substance use disorder. Understanding dopamine is key to understanding ADHD.
1:45Tech companies deliberately exploit dopamine rewards to keep users hooked on apps and screens. This episode examines how engineered addiction contributes to rising depression rates across all ages.
0:55The DSM defines major depression based on symptoms lasting just 14 days. This episode questions whether that threshold truly captures chronic illness versus temporary life setbacks.
0:25New therapies like ketamine, esketamine, and TMS focus on the brain's actual structure. Research shows ketamine may help grow new neurons, offering hope beyond traditional medications.
0:45Major Depressive Disorder first appeared in psychiatry's diagnostic manual in 1980. This episode traces how depression evolved from an unclassified condition to one of the most common diagnoses today.
1:41Ritalin works by increasing dopamine in people who are dopamine-deficient — which is why stimulants calm hyperactive patients rather than making them more hyper. Understanding this changes the ADHD conversation.
0:30A look at how TMS therapy evolved from an uncovered procedure in 2012 to a widely recognized treatment that keeps patients out of hospitals and prevents therapeutic misadventures.
1:26Spravato (esketamine) offers rapid-onset antidepressant effects — sometimes within a single treatment — making it especially valuable for patients with suicidal ideation who can't wait weeks for relief.
1:10Unlike SSRIs that take weeks to work, Spravato (esketamine) provides rapid-onset antidepressant effects — critical for patients with suicidal thoughts who need immediate relief.
1:40Research shows SSRIs may double the risk of suicide in adolescents, making accurate diagnosis critical. TMS offers a safer alternative for teens whose depression may actually be early-stage bipolar disorder.
2:46Sexual dysfunction, weight gain, and emotional blunting are common but underreported SSRI side effects. This frank conversation explores why many patients abandon antidepressants.
0:18An overview of two FDA-cleared therapies — Transcranial Magnetic Stimulation (TMS) and Spravato (esketamine) — and how they help patients recover from treatment-resistant depression.
0:19TMS is indicated for treatment-resistant depression — patients who have failed multiple antidepressant classes — and also carries an indication for patients struggling with suicidal thoughts.
0:33TMS therapy has been approved for adolescents aged 15 and above as an augmenting treatment, meaning teens may not need to endure multiple medication failures before trying TMS.
1:01A candid discussion about the cycle of medication trials, the limitations of traditional prescribing, and how TMS emerged as a recognized alternative for treatment-resistant patients.
2:22Only a third of patients on antidepressants achieve a meaningful response, and prolonged use may actually worsen depression — a phenomenon called iatrogenic or tardive depression.
0:52Many patients arrive at psychiatric care after years of failed medication trials from primary care providers. This episode explores why seeing a specialist sooner can change outcomes.
2:32The decades-old theory that depression stems from serotonin deficiency hasn't held up. This episode explains how the antidepressant movement may have been built on a flawed observation from tuberculosis medications.
0:33Approved since 2007 and adopted by Medicare in 2012, TMS therapy has a strong track record of safety, effectiveness, and minimal side effects for treating depression.
Restore Brain is now serving patients in the greater St. Louis area. Our new clinic at 11477 Olde Cabin Rd offers both TMS therapy and Spravato treatment with the same patient-centered care our DFW patients know.
Both target the glutamate system, but Spravato and IV ketamine differ in important ways — FDA approval, administration, insurance coverage, and safety protocols. Here's what patients should know.
Everything you need to know about Transcranial Magnetic Stimulation — how it works, what to expect, and who it can help. A comprehensive overview for patients considering TMS for treatment-resistant depression.
